Patents by Inventor Sherie Duncan

Sherie Duncan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-TREM2 antibodies and methods of use thereof
    Patent number: 12240902
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: March 4, 2025
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • CD3 T-Cell Engagers and Methods of Use
    Publication number: 20230295310
    Abstract: Anti-CD3 antibodies for use in the diagnosis or treatment of hyperproliferative or autoimmune disorders methods of using the same for detecting and/or treating a hyperproliferative or autoimmune disorders.
    Type: Application
    Filed: March 20, 2023
    Publication date: September 21, 2023
    Applicant: AbCellera Biologics Inc.
    Inventors: Lindsay DEVORKIN, Aaron Paul YAMNIUK, Bryan Crawford BARNHART, Wei WEI, Kevin HEYRIES, Harveer DHUPAR, Sherie DUNCAN, Timothy M. JACOBS
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220119522
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: April 21, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220073609
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: March 10, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh